What is the DSIP peptide dosage?

There is no approved DSIP dosage. Historical human sleep experiments most often used 25 nmol/kg — about 21.2 µg/kg — by intravenous infusion, while the FDA's broader review found IV exposure from 25 to 150 nmol/kg. Those were study protocols, not clinical recommendations, and they do not establish a dose for the subcutaneous vials sold online.

Is there a DSIP peptide dosing chart for sleep?

There is a chart of published study doses above, but no evidence-based treatment chart. The distinction matters: the studies were small, old and inconsistent; the FDA called the insomnia evidence inconclusive or preliminary; and the best controlled 16-person study concluded that short-term DSIP was unlikely to offer major therapeutic benefit.

Was DSIP studied as a subcutaneous injection?

Not in the human clinical safety record the FDA reviewed. The agency found several human studies using intravenous DSIP but no clinical studies with safety information for the proposed subcutaneous route. An animal subcutaneous result or a retail convention cannot fill that human evidence gap.

How many syringe units is 100 mcg of DSIP?

It depends entirely on concentration. A 5 mg vial contains 5,000 mcg. With 2 mL of liquid it is 2,500 mcg/mL, so 100 mcg is 0.04 mL or 4 units on a U-100 syringe. With 1 mL it becomes 2 units. The 100 mcg figure is only an arithmetic example here, not a recommendation.

Does DSIP improve sleep?

The human evidence is inconsistent and too weak to establish that. Some small studies reported changes in selected sleep measurements, while others found little clinical significance. In 2026 the FDA concluded that the available evidence was insufficient to support emideltide for chronic insomnia and described the results as inconclusive and at best preliminary.

DSIP Peptide Dosage Calculator and Dosing Chart

Emideltide, a nine-amino-acid peptide studied decades ago by intravenous infusion. Small insomnia trials were inconsistent, and no human subcutaneous dose has been studied.

Written by Kashif Khan, who builds and maintains this site and is not a clinician. Every figure links to its primary source.

Not approved

Not FDA-approved; FDA review weighed against 503A listing

The FDA evaluated emideltide — another name for DSIP — for compounded subcutaneous products proposed for chronic insomnia, narcolepsy and opioid withdrawal. Its May 2026 briefing concluded that the criteria weighed against placing emideltide free base or acetate on the 503A Bulks List. The FDA's current safety-risk page lists emideltide under nominations that were withdrawn and says it lacks sufficient information to know whether the proposed route would harm humans.

No approved human dose exists for this compound in any country. The figures below are the doses used in named published studies, reproduced for reference only. Doses given to rats or mice do not convert to a human dose. The FDA has stated that labelling a product “research use only” or “not for human consumption” does not change its legal status when the seller's own marketing shows it is intended for people.

Calculator inputs

Set up your vial

Enter the label, dilution and dose. The result updates as you type.

Syringe volume

DSIP in the vial

100 mcg is a calculator example, not a studied or recommended subcutaneous dose

Bacteriostatic water to add

Dose per injection

No approved human dose exists for this compound. The dose shown is only a calculator input, not a recommendation or starting point.

More optionsReverse calculation, schedule and cost

Enter the bacteriostatic water you added and get the volume to draw.

Injections per week

Discard afterdays

Vial priceoptional

Draw to

4units(0.04 mL)

Concentration: 2500 mcg/mL
Water added: 2 mL
Doses in vial: 50

How the concentration is calculated

This divides the peptide by the water you add. The powder occupies a little volume of its own, which is negligible on a typical vial but not on one with a heavy bulking agent. When a product label states a concentration, use the label’s number.

A 4-unit draw is very small. Adding more water raises the volume and makes the dose easier to measure accurately.

Key facts

Molecular weight: 848.8 DaFree-base emideltide: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. The acetate salt adds a variable amount of acetate and should not be treated as the same molecular mass.
Half-life: Not published. No accessible human pharmacokinetic study reports one, so any specific figure quoted elsewhere has no primary source behind it.
Also sold as: delta sleep-inducing peptide, emideltide

Doses used in published studies

These are reproduced for reference. They are not recommendations, and an animal dose in mg/kg does not convert to a human dose.

humanintravenous, in the afternoon before three consecutive study nights

25 nmol/kg (about 21.2 µg/kg)

Bes et al., 1992: double-blind matched-pairs study in 16 people with chronic insomnia. Objective sleep efficiency and latency changed weakly, subjective sleep quality did not, and the authors concluded that short-term DSIP was unlikely to be of major therapeutic benefit.

humanintravenous infusion over 20 minutes, morning administration

25 nmol/kg (about 21.2 µg/kg)

Schneider-Helmert and Schoenenberger, 1981: double-blind crossover experiment in six healthy volunteers. This was an acute physiology study, not evidence for a nightly subcutaneous protocol.

How good is the evidence?

Old, small and route-specific. The FDA found human studies covering 209 subjects exposed to 25–150 nmol/kg intravenously for 1–15 days, but judged the effectiveness evidence insufficient and the insomnia findings inconclusive or preliminary. It found no clinical safety data for the proposed subcutaneous route. A 1992 double-blind study in 16 people with chronic insomnia found only weak changes and concluded that short-term DSIP was unlikely to provide major therapeutic benefit.

DSIP peptide dosing chart: what was actually studied

The repeatable figure in the human sleep literature is 25 nmol/kg by intravenous infusion, equivalent to about 21.2 µg/kg for the 848.8 Da free-base peptide. That number appears in small experiments with different timing and infusion durations. It is a historical study dose, not an approved dose and not a subcutaneous dosing protocol.

Across the larger safety record reviewed by the FDA, intravenous exposure ranged from 25 to 150 nmol/kg for 1 to 15 days. Pooling those experiments does not create a dosing range for insomnia: the studies differed in population, purpose and design, and the FDA concluded that evidence of effectiveness was insufficient.

Why the calculator does not recommend a DSIP injection schedule

Retail DSIP vials are generally discussed as subcutaneous injections, but the human literature the FDA identified used intravenous administration. FDA reviewers found no clinical studies containing safety information for the proposed subcutaneous route. Changing the route changes absorption, exposure and risk, so an IV study dose cannot simply be copied onto a subcutaneous syringe.

The calculator therefore does one limited job: it converts the mass stated on a vial and the liquid added into concentration, millilitres and U-100 syringe units. Its 100 mcg starting value is an editable arithmetic example. It is not a dose recommendation, and the historical study table is kept separate so the two are not mistaken for each other.

What the FDA found about DSIP safety and effectiveness

For chronic insomnia, the FDA described the evidence as inconclusive and at best preliminary, citing small samples, inconsistent results, varying regimens and weak study methods. In the 16-person double-blind study, the statistically significant changes were weak, subjective sleep quality did not improve, and the authors themselves said major therapeutic benefit was unlikely.

The FDA also flagged potential immunogenicity from peptide aggregation and impurities in an injected product. Intravenous insomnia studies reported no significant adverse effects, but withdrawal studies recorded transient headache, nausea and vertigo, plus cases of hypotension. None of that resolves the safety of a subcutaneous product made and used differently.

Common questions

Sources

Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.

RegulatorFDA Pharmacy Compounding Advisory Committee· 2026-05-11
FDA evaluation of emideltide (DSIP)-related bulk drug substances for the 503A Bulks List
RegulatorFDA
Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
Published studyNeuropsychobiology· 1992
Bes F et al. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients — a double-blind study
Published studyInternational Journal of Clinical Pharmacology, Therapy, and Toxicology· 1981
Schneider-Helmert D, Schoenenberger GA. Acute and delayed effects of DSIP on human sleep behavior